ABL Bio Secures Chinese Patent for Anti-ROR1 Monoclonal Antibodies
Guaranteed rights in China for anti-ROR1 monoclonal antibodies and their use until 2039
ABL Bio, led by CEO Lee Sang-hoon, a specialized company in bispecific antibodies, announced the successful registration of a Chinese patent for their anti-ROR1 antibody. This antibody effectively inhibits ROR1, a protein found in various carcinomas including solid cancer and blood cancer, making it a promising development in the fight against cancer.
The patent grants ABL Bio exclusive rights until 2039, and the company is currently pursuing patent registration in other countries such as the United States, Europe, Korea, Japan, and China. This recognition further solidifies ABL Bio’s position as a significant player in the global market for anti-cancer therapeutics.
ABL Bio’s anti-ROR1 antibody is particularly notable for its ability to target different types of cancer. ROR1 is known to be overexpressed in various cancers, making it an attractive target for therapeutic interventions. The company has also partnered with LegoChem Bio to develop the ROR1 ADC pipeline ABL202 (CS5001, LCB71), which has shown promising results in clinical trials.
ABL202 has been licensed to CStone Pharmaceuticals, a public company listed in Hong Kong, and is currently undergoing phase 1 clinical trials. Preliminary data presented at the World ADC London conference confirms its superior anti-tumor efficacy compared to other competitors’ ADC benchmarks at lower doses.
CEO Lee Sang-hoon remarks on the significance of the Chinese market, stating that China has twice the number of cancer patients as the United States, the current leader in the anti-cancer market. Furthermore, China’s fast-track approval system has paved the way for 31 out of 49 new drugs approved in 2020. This makes the Chinese market both lucrative and attractive for drug developers.
In addition to the anti-ROR1 monoclonal antibodies, ABL Bio has a robust pipeline of other promising therapeutics in various stages of development. With over 14 global clinical trials and ongoing research, the company is committed to advancing the field of oncology and improving patient outcomes.
[Source: Biotimes; Kim Su-jin, journalist]
Disclaimer: This article is the intellectual property of Biotimes and reproduction or redistribution without authorization is strictly prohibited.
Guaranteed rights in China for anti-ROR1 monoclonal antibodies and their use until 2039
Chinese anti-cancer market was evaluated attractively due to high market performance and better approval system
(Photo = ABL Bio)
[바이오타임즈] ABL Bio (CEO Lee Sang-hoon), a company specializing in bispecific antibodies, announced on the 5th that it has completed the registration of a Chinese patent for an anti-ROR1 antibody that inhibits ROR1, which is being – say in various carcinomas such as solid cancer. and blood cancer, and its use.
The patent right is guaranteed until 2039, and examinations for patent registration are underway in many countries, including the United States and Europe, as well as Korea, Japan, and China, which were previously granted.
ROR1 is an attention-grabbing target as it can target different types of cancer by being overexpressed in different types of cancer from solid to hematological cancer. ABL Bio also developed the ROR1 ADC pipeline ABL202 (CS5001, LCB71) through collaboration with LegoChem Bio. . ABL202 is competitive by combining ABL Bio’s outstanding ROR1 antibody with LegoChem Bio’s blood-stable linker and Pro PBD in an optimal ratio, and this is being confirmed as clinical trials progress.
ABL202 has transferred technology to CStone Pharmaceuticals, a listed company in Hong Kong, and is undergoing phase 1 clinical trials.
At the World ADC London held in London in March this year, it was confirmed through the non-clinical data presented by C-Stone that it exhibits higher anti-tumor efficacy compared to competitors’ ADC benchmarks at a lower dose. additional data will be made public.
Lee Sang-hoon, CEO of ABL Bio, said, “China has more than twice as many cancer patients as the United States, which is the No. 1 anti-cancer market, and nearly five times as many patients die from cancer . As a result, 31 out of 49 new drugs approved in 2020 were approved through the fast-track approval system, and China is an attractive market with high marketability and a system to support it.” out, also meaningful.”
Meanwhile, ABL001 (VEGFxDLL4), ABL111 (Claudin18.2×4-1BB), ABL503 (PD-L1x4-1BB), ABL105 (HER2x4-1BB), ABL202 (ROR1 ADC), ABL301 (a-synxIGF1R), ABL1 Bio ( B7-H4x4-1BB), and there are more than 14 global clinical trials in the US, China, Australia and Korea for more than 7 pipelines, and pipelines such as ABL104 (EGFRx4-1BB) are also preparation for clinical entry. ongoing In addition, research and development of a number of non-clinical pipelines, including ABL102 (ROR1x4-1BB) and ABL602 (CLL1xCD3), is also underway.
[바이오타임즈=김수진 기자] sjkimcap@biotimes.co.kr
Copyright © Biotimes Unauthorized reproduction and redistribution prohibited
#ABL #Bio #completed #Chinese #patent #registration #ROR1 #antibody
